{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:40:57Z","timestamp":1792453257500,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02899-8","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:02:23Z","timestamp":1792450943000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Entinostat plus exemestane for hormone receptor-positive advanced breast cancer: long-term overall survival results from the EOC103A3101 randomized controlled trial"],"prefix":"10.1038","volume":"11","author":[{"given":"Jiani","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6148-9186","authenticated-orcid":false,"given":"Xichun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3911-748X","authenticated-orcid":false,"given":"Min","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changping","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-337X","authenticated-orcid":false,"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,20]]},"reference":[{"key":"2899_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2899_CR2","first-page":"480","volume":"73","author":"LA Huppert","year":"2023","unstructured":"Huppert, L. A., Gumusay, O., Idossa, D. & Rugo, H. S. Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J. Clin. 73, 480\u2013515 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"2899_CR3","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(20)30165-3","volume":"395","author":"LM Spring","year":"2020","unstructured":"Spring, L. M. et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet 395, 817\u2013827 (2020).","journal-title":"Lancet"},{"key":"2899_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000508675","volume":"15","author":"AD Hartkopf","year":"2020","unstructured":"Hartkopf, A. D., Grischke, E. M. & Brucker, S. Y. Endocrine-resistant breast cancer: mechanisms and treatment. Breast Care 15, 347\u2013354 (2020).","journal-title":"Breast Care"},{"key":"2899_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.759150","volume":"11","author":"JY Kim","year":"2021","unstructured":"Kim, J. Y. et al. Which clinicopathologic parameters suggest primary resistance to Palbociclib in combination with letrozole as the first-line treatment for hormone receptor-positive, HER2-Negative advanced breast cancer?. Front Oncol. 11, 759150 (2021).","journal-title":"Front Oncol."},{"key":"2899_CR6","doi-asserted-by":"crossref","unstructured":"Llombart-Cussac, A. et al. Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])\/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial. J. Clin. Oncol. 41, 1001\u20131001 (2023).","DOI":"10.1200\/JCO.2023.41.16_suppl.1001"},{"key":"2899_CR7","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1200\/JCO.23.01940","volume":"42","author":"EL Mayer","year":"2024","unstructured":"Mayer, E. L. et al. PACE: a randomized phase II study of Fulvestrant, Palbociclib, and Avelumab after progression on cyclin-dependent kinase 4\/6 inhibitor and aromatase inhibitor for hormone receptor-positive\/human epidermal growth factor receptor-negative metastatic breast cancer. J. Clin. Oncol. 42, 2050\u20132060 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2899_CR8","doi-asserted-by":"publisher","first-page":"LBA1004","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA1004","volume":"40","author":"K Kalinsky","year":"2022","unstructured":"Kalinsky, K. et al. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4\/6 inhibition (CDK 4\/6i) in patients (pts) with unresectable or hormone receptor\u2013positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. J. Clin. Oncol. 40, LBA1004 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2899_CR9","doi-asserted-by":"publisher","first-page":"LBA1001","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1001","volume":"42","author":"K Kalinsky","year":"2024","unstructured":"Kalinsky, K. et al. Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2-advanced breast cancer following progression on a prior CDK4\/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial. J. Clin. Oncol. 42, LBA1001 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2899_CR10","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520\u2013529 (2012).","journal-title":"N. Engl. J. Med."},{"key":"2899_CR11","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s10549-024-07324-8","volume":"206","author":"R S\u00e1nchez-Bayona","year":"2024","unstructured":"S\u00e1nchez-Bayona, R. et al. Everolimus plus endocrine therapy beyond CDK4\/6 inhibitors progression for HR+\u2009\/HER2- advanced breast cancer: a real-world evidence cohort. Breast Cancer Res. Treat. 206, 551\u2013559 (2024).","journal-title":"Breast Cancer Res. Treat."},{"key":"2899_CR12","doi-asserted-by":"crossref","unstructured":"Kumar, R., Paul, A.M., Rameshwar, P. & Pillai, M.R. Epigenetic dysregulation at the crossroad of women\u2019s cancer. Cancers 11, 1193 (2019).","DOI":"10.3390\/cancers11081193"},{"key":"2899_CR13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S1470-2045(19)30164-0","volume":"20","author":"Z Jiang","year":"2019","unstructured":"Jiang, Z. et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 806\u2013815 (2019).","journal-title":"Lancet Oncol."},{"key":"2899_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/tbcr-23-31","volume":"4","author":"Q Zhang","year":"2023","unstructured":"Zhang, Q. et al. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial. Transl. Breast Cancer Res. 4, 18 (2023).","journal-title":"Transl. Breast Cancer Res."},{"key":"2899_CR15","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1158\/0008-5472.CAN-10-2458","volume":"71","author":"GJ Sabnis","year":"2011","unstructured":"Sabnis, G. J. et al. Functional activation of the estrogen receptor-\u03b1 and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res. 71, 1893\u20131903 (2011).","journal-title":"Cancer Res."},{"key":"2899_CR16","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1158\/1535-7163.MCT-13-0345","volume":"12","author":"GJ Sabnis","year":"2013","unstructured":"Sabnis, G. J. et al. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2. Mol. Cancer Ther. 12, 2804\u20132816 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"2899_CR17","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","volume":"31","author":"DA Yardley","year":"2013","unstructured":"Yardley, D. A. et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J. Clin. Oncol. 31, 2128\u20132135 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2899_CR18","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1200\/JCO.21.00944","volume":"39","author":"RM Connolly","year":"2021","unstructured":"Connolly, R. M. et al. E2112: randomized phase III trial of endocrine therapy plus entinostat or placebo in hormone receptor-positive advanced breast cancer. a trial of the ECOG-ACRIN cancer research group. J. Clin. Oncol. 39, 3171\u20133181 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2899_CR19","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1016\/j.apsb.2023.02.001","volume":"13","author":"B Xu","year":"2023","unstructured":"Xu, B. et al. Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer:a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial. Acta Pharm. Sin. B. 13, 2250\u20132258 (2023).","journal-title":"Acta Pharm. Sin. B."},{"key":"2899_CR20","unstructured":"The Society of Breast Cancer China Anti-Cancer Association, Breast Oncology Group of the Oncology Branch of the Chinese Medical Association. Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2024 edition). China Oncol. 33, 1092\u20131187 (2023)."},{"key":"2899_CR21","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.3390\/cancers14081903","volume":"14","author":"S Joshi","year":"2022","unstructured":"Joshi, S., Garlapati, C. & Aneja, R. Epigenetic determinants of racial disparity in breast cancer: looking beyond genetic alterations. Cancers 14, 1903 (2022).","journal-title":"Cancers"},{"key":"2899_CR22","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/ejhg.2013.38","volume":"21","author":"D Barzan","year":"2013","unstructured":"Barzan, D. et al. Comparison of genetic variation of breast cancer susceptibility genes in Chinese and German populations. Eur. J. Hum. Genet 21, 1286\u20131292 (2013).","journal-title":"Eur. J. Hum. Genet"},{"key":"2899_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33351-4","volume":"13","author":"F Ma","year":"2022","unstructured":"Ma, F., Laster, K. & Dong, Z. The comparison of cancer gene mutation frequencies in Chinese and U.S. patient populations. Nat. Commun. 13, 5651 (2022).","journal-title":"Nat. Commun."},{"key":"2899_CR24","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10549-025-07737-z","volume":"212","author":"NM Mustafa","year":"2025","unstructured":"Mustafa, N. M. et al. Efficacy and safety of entinostat plus exemestane in hormone receptor-positive breast cancer: a systematic review meta-analysis of randomized controlled trials. Breast Cancer Res. Treat. 212, 417\u2013426 (2025).","journal-title":"Breast Cancer Res. Treat."},{"key":"2899_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/15592294.2024.2309824","volume":"19","author":"J Krushkal","year":"2024","unstructured":"Krushkal, J. et al. Association of changes in expression of HDAC and SIRT genes after drug treatment with cancer cell line sensitivity to kinase inhibitors. Epigenetics 19, 2309824 (2024).","journal-title":"Epigenetics"},{"key":"2899_CR26","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner, N. C. et al. Overall survival with Palbociclib and Fulvestrant in advanced breast cancer. N. Engl. J. Med. 379, 1926\u20131936 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2899_CR27","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1001\/jamaoncol.2019.4782","volume":"6","author":"GW Sledge Jr.","year":"2020","unstructured":"Sledge, G. W. Jr. et al. The effect of Abemaciclib Plus Fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 6, 116\u2013124 (2020).","journal-title":"JAMA Oncol."},{"key":"2899_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","volume":"373","author":"NC Turner","year":"2015","unstructured":"Turner, N. C. et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 373, 209\u2013219 (2015).","journal-title":"N. Engl. J. Med."},{"key":"2899_CR29","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17, 425\u2013439 (2016).","journal-title":"Lancet Oncol."},{"key":"2899_CR30","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S1470-2045(19)30817-4","volume":"21","author":"RH Jones","year":"2020","unstructured":"Jones, R. H. et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 21, 345\u2013357 (2020).","journal-title":"Lancet Oncol."},{"key":"2899_CR31","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner, N. C. et al. Capivasertib in hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 388, 2058\u20132070 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2899_CR32","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1470-2045(22)00284-4","volume":"23","author":"SJ Howell","year":"2022","unstructured":"Howell, S. J. et al. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. Lancet Oncol. 23, 851\u2013864 (2022).","journal-title":"Lancet Oncol."},{"key":"2899_CR33","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3892\/or.2012.1881","volume":"28","author":"Z Liu","year":"2012","unstructured":"Liu, Z. et al. Lysosomal membrane protein TMEM192 deficiency triggers crosstalk between autophagy and apoptosis in HepG2 hepatoma cells. Oncol. Rep. 28, 985\u2013991 (2012).","journal-title":"Oncol. Rep."},{"key":"2899_CR34","doi-asserted-by":"publisher","first-page":"877","DOI":"10.14348\/molcells.2016.0161","volume":"39","author":"RY Shyu","year":"2016","unstructured":"Shyu, R. Y. et al. Tazarotene-induced gene 1 enhanced cervical cell autophagy through transmembrane protein 192. Mol. Cells 39, 877\u2013887 (2016).","journal-title":"Mol. Cells"},{"key":"2899_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.drudis.2021.08.004","volume":"27","author":"S Patra","year":"2022","unstructured":"Patra, S., Praharaj, P. P., Klionsky, D. J. & Bhutia, S. K. Vorinostat in autophagic cell death: a critical insight into autophagy-mediated, -associated and -dependent cell death for cancer prevention. Drug Discov. Today 27, 269\u2013279 (2022).","journal-title":"Drug Discov. Today"},{"key":"2899_CR36","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.1073\/pnas.1204429109","volume":"109","author":"N Gammoh","year":"2012","unstructured":"Gammoh, N. et al. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc. Natl. Acad. Sci. USA 109, 6561\u20136565 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2899_CR37","doi-asserted-by":"crossref","unstructured":"Mrakovcic, M., Kleinheinz, J. & Frohlich, L.F. p53 at the crossroads between different types of HDAC inhibitor-mediated cancer cell death. Int. J. Mol. Sci. 20, 2415 (2019).","DOI":"10.3390\/ijms20102415"},{"key":"2899_CR38","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10620-023-08032-x","volume":"69","author":"X Yang","year":"2024","unstructured":"Yang, X. et al. Identification of molecular targets of bile acids acting on colorectal cancer and their correlation with immunity. Dig. Dis. Sci. 69, 123\u2013134 (2024).","journal-title":"Dig. Dis. Sci."},{"key":"2899_CR39","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1039\/C9FO01168D","volume":"10","author":"B Pang","year":"2019","unstructured":"Pang, B. et al. Prediction of new targets and mechanisms for quercetin in the treatment of pancreatic cancer, colon cancer, and rectal cancer. Food Funct. 10, 5339\u20135349 (2019).","journal-title":"Food Funct."},{"key":"2899_CR40","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.21037\/tcr-23-2281","volume":"13","author":"Y Ye","year":"2024","unstructured":"Ye, Y. & Xu, G. Construction of a new prognostic model for colorectal cancer based on bulk RNA-seq combined with The Cancer Genome Atlas data. Transl. Cancer Res. 13, 2704\u20132720 (2024).","journal-title":"Transl. Cancer Res."},{"key":"2899_CR41","volume":"12","author":"F Zhang","year":"2025","unstructured":"Zhang, F. et al. Targeting histone deacetylase 11 with a highly selective inhibitor for the treatment of MASLD. Adv. Sci. (Weinh.) 12, e2412903 (2025).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"2899_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1623211","volume":"16","author":"J Li","year":"2025","unstructured":"Li, J. et al. HDAC inhibitor MS275 reprograms metabolism to induce differentiation and suppress proliferation in hepatocellular carcinoma. Front. Immunol. 16, 1623211 (2025).","journal-title":"Front. Immunol."},{"key":"2899_CR43","doi-asserted-by":"publisher","first-page":"D1211","DOI":"10.1093\/nar\/gky869","volume":"47","author":"J Ma","year":"2019","unstructured":"Ma, J. et al. iProX: an integrated proteome resource. Nucleic Acids Res. 47, D1211\u2013D1217 (2019).","journal-title":"Nucleic Acids Res."},{"key":"2899_CR44","doi-asserted-by":"publisher","first-page":"D1522","DOI":"10.1093\/nar\/gkab1081","volume":"50","author":"T Chen","year":"2022","unstructured":"Chen, T. et al. iProX in 2021: connecting proteomics data sharing with big data. Nucleic Acids Res. 50, D1522\u2013D1527 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02899-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02899-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02899-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:02:25Z","timestamp":1792450945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02899-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2899"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02899-8","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hongyan Shang is an employee of Taizhou EOC Pharma Co., Ltd, Taizhou, China. All other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"457"}}